ASMB vs ATOS

Assembly Biosciences, Inc. vs Atossa Therapeutics, Inc. — Valuation Comparison 2026

ASMB

Biotechnology
Assembly Biosciences, Inc.
Quality
6.1
out of 10
Value Trap
18
SAFE
Price
$27.73
Last close
Models
9/13
Active
VS

ATOS

Biotechnology
Atossa Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$5.19
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ASMB Fair ValueASMB Upside ATOS Fair ValueATOS Upside
Bayesian DCF Intrinsic $6.31 -77.3% $3.40 -34.4%
First Chicago Scenario $5.49 -80.2% $14.39 +189.6%
ML-RIV Intrinsic $3.04 -89.0% $0.52 -90.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ASMB vs ATOS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ASMB vs ATOS — Which Stock Is More Undervalued?

ASMB scores higher with a 6.1/10 quality rating vs ATOS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Assembly Biosciences, Inc. (ASMB) and Atossa Therapeutics, Inc. (ATOS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ASMB currently trades at $27.73 with a QOC of 6.1/10, while ATOS trades at $5.19 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).